4.7 Article

Outcomes in Patients With Transcatheter Aortic Valve Replacement and Left Main Stenting The TAVR- LM Registry

Journal

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
Volume 67, Issue 8, Pages 951-960

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/j.jacc.2015.10.103

Keywords

aortic valve stenosis; coronary artery disease; percutaneous coronary intervention; transcatheter aortic valve replacement

Funding

  1. National Institutes of Health [K23 HL116660]
  2. Edwards Lifesciences
  3. Direct Flow Medical
  4. Abbott
  5. Access Closure
  6. AGA
  7. Angiomed
  8. Aptus
  9. Atrium
  10. Avinger
  11. Bard
  12. Boston Scientific
  13. Bridgepoint
  14. Cardiac Dimensions
  15. CardioKinetix
  16. CardioMEMS
  17. Coherex
  18. Contego
  19. Covidien
  20. CSI
  21. CVRx
  22. EndoCross
  23. ev3
  24. FlowCardia
  25. Gardia
  26. Gore
  27. Guided Delivery Systems
  28. InSeal Medical
  29. Lumen Biomedical
  30. HLT
  31. Lifetech
  32. Lutonix
  33. Maya Medical
  34. Medtronic
  35. NDC
  36. Occlutech
  37. Osprey
  38. Ostial
  39. PendraCare
  40. pfm Medical
  41. Recor
  42. ResMed
  43. Rox Medical
  44. SentreHEART
  45. Spectranetics
  46. SquareOne
  47. Svelte Medical Systems
  48. Trireme
  49. Trivascular
  50. Venus Medical
  51. Veryan
  52. Vessix
  53. Cook
  54. AstraZeneca
  55. Bristol-Myers Squibb
  56. Daiichi-Sankyo/Eli Lilly
  57. GlaxoSmithKline
  58. Janssen
  59. Merck/Schering-Plough
  60. Regeneron
  61. St. Jude Medical

Ask authors/readers for more resources

BACKGROUND A percutaneous approach with transcatheter aortic valve replacement (TAVR) and percutaneous coronary intervention (PCI) of the left main coronary artery (LM) is frequently used in high-risk patients with coexisting aortic stenosis and LM disease. Outcomes of TAVR plus LM PCI have not been previously reported. OBJECTIVES The primary objective of the TAVR-LM registry is to evaluate clinical outcomes in patients undergoing TAVR plus LM PCI. METHODS Clinical, echocardiographic, computed tomographic, and angiographic characteristics were retrospectively collected in 204 patients undergoing TAVR plus LM PCI. In total, 128 matched patient pairs were generated by performing 1: 1 case-control matching between 167 patients with pre-existing LM stents undergoing TAVR and 1,188 control patients undergoing TAVR without LM revascularization. RESULTS One-year mortality (9.4% vs. 10.2%, p = 0.83) was similar between the TAVR plus LM PCI cohort and matched controls. One-year mortality after TAVR plus LM PCI was not different in patients with unprotected compared with protected LMs (7.8% vs. 8.1%, p = 0.88), those undergoing LM PCI within 3 months compared with those with LM PCI greater than 3 months before TAVR (7.4% vs. 8.6%, p = 0.61), and those with ostial versus nonostial LM stents (10.3% vs. 15.6%, p = 0.20). Unplanned LM PCI performed because of TAVR-related coronary complication, compared with planned LM PCI performed for pre-existing LM disease, resulted in increased 30-day (15.8% vs. 3.4%, p = 0.013) and 1-year (21.1% vs. 8.0%, p - 0.071) mortality. CONCLUSIONS Despite the anatomic proximity of the aortic annulus to the LM, TAVR plus LM PCI is safe and technically feasible, with short-and intermediate-term clinical outcomes comparable with those in patients undergoing TAVR alone. These results suggest that TAVR plus LM PCI is a reasonable option for patients who are at high risk for surgery. (C) 2016 by the American College of Cardiology Foundation.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available